Journal: Cancer Research

Article Title: Disruption of Prostaglandin E2 Signaling in Cancer-Associated Fibroblasts Limits Mammary Carcinoma Growth but Promotes Metastasis

doi: 10.1158/0008-5472.can-21-2116

Figure Lengend Snippet: Figure 1. mPGES-1 ablation limits tumorprogressionand increases CAFabundance. A,Tumorburden(percentageoftumor weightrelativetobodyweight)in20-week-oldWTand mPGES-1 KO PyMT mice is shown. Data are means SEM; n ¼ 6. B, Representative hematoxylin and eosin images of the center and invasive margin of WT and mPGES-1 KO PyMT tumors. Scale bars, 50 mm. C–J, Tumor sections were stained for CAF markers and analyzed using PhenOptics. C, Representative images show tissue segmentationintotumor(blue),stroma(green),andnotissue(red).Scalebars,100mm.D,Quantificationofstromalcontent.E,Representativeimages showfluorescence staining of CAF and proliferation markers in WT and mPGES-1 KO PyMT tumor sections, aSma (green), Vim (yellow), Col-1 (cyan), Fsp-1 (purple), Ki67 (red), and DAPI (white). Scale bars, 100 mm. F–I, Quantification of markers aSMA (F), Vim (G), Col-1 (H), and Ki67 (I) in stromal cells. J, Quantification of Ki67 I tumor cells. Data are means SEM; individual data points are high-power fields of at least six individual tumors per genotype. , P < 0.05; , P < 0.01; , P < 0.001; Mann–Whitney test.

Article Snippet: For immunofluorescence analysis of PyMT organoids, Organoids were washed and fixed overnight in 4% PFA at 4 C, then permeabilized/blocking using 0.3% Triton X-100 (Applichem) with 5% donkey serum (Sigma-Aldrich) in PBS for 12 hours at 4 C. Organoids were stained in PBS with 0.5% donkey serum and 0.1% Triton X-100, with the following antibodies: Anti–E-cad-AF647 (BioLegend), anti– vimentin-APC (R&D Systems), Ki67 (Abcam), phalloidin-AF488 (Thermo Fisher Scientific), and Hoechst 33342 (Sigma-Aldrich).

Techniques: Staining, MANN-WHITNEY

Journal: Cancer Research

Article Title: Disruption of Prostaglandin E2 Signaling in Cancer-Associated Fibroblasts Limits Mammary Carcinoma Growth but Promotes Metastasis

doi: 10.1158/0008-5472.can-21-2116

Figure Lengend Snippet: Figure 7. EP3/Tak1L in fibroblasts promotes tumor growth but limits EMT. A, Experimental setup. PyMT organoids were cultured in control medium alone, treated with 20 ng/mL TGFb, or cultured in supernatants of WT, EP3 KO, Map3k7cl KD MGFs for 96 hours; n ¼ 6 biological replicates each. Organoid phenotype was analyzed by immunofluorescence staining and confocal microscopy, or qPCR. B, Representative images of organoids after culturing for 96 hours. Scale bars, 30 mm. C, Quantification of Hoechst fluorescence, indicating organoid size. D, Quantification of Ki67þ cells by FACS. E, Ratio between vimentin (Vim) and E-cadherin (Ecad). F, Distance of Vim-positive cells from spheroid surface (mean). G andH, mRNA expression of Zeb2 and Lef1 normalized to organoids receiving supernatants of WT MGF. I–K, Lungs of 20-week-old WT or mPGES-1 KO (n ¼ 3) PyMT mice were harvested and analyzed for metastasis. I, PyMT mRNA expression quantified by qPCR (WT, n ¼ 4; mPGES-1 KO, n ¼ 3). J, Representative fluorescence images of metastasis in lung sections showing Ki67 (red), aSma (green), Pan-ck (yellow), and DAPI (white). Scale bars, 800 and 100 mm. K, Lung sections (10 sections for each animal) were analyzed using Inform software to determine the metastasis foci (n ¼ 6 each). All data are means SEM. , P < 0.05; , P < 0.01; , P < 0.001; n.s., nonsignificant; one-way ANOVA with Bonferroni’s correction (C–E), one-sample t test (F and G), or Mann–Whitney test (I and K).

Article Snippet: For immunofluorescence analysis of PyMT organoids, Organoids were washed and fixed overnight in 4% PFA at 4 C, then permeabilized/blocking using 0.3% Triton X-100 (Applichem) with 5% donkey serum (Sigma-Aldrich) in PBS for 12 hours at 4 C. Organoids were stained in PBS with 0.5% donkey serum and 0.1% Triton X-100, with the following antibodies: Anti–E-cad-AF647 (BioLegend), anti– vimentin-APC (R&D Systems), Ki67 (Abcam), phalloidin-AF488 (Thermo Fisher Scientific), and Hoechst 33342 (Sigma-Aldrich).

Techniques: Cell Culture, Control, Staining, Confocal Microscopy, Expressing, Software, MANN-WHITNEY

Journal: Journal of Experimental & Clinical Cancer Research : CR

Article Title: Targeting CXCR4 by a selective peptide antagonist modulates tumor microenvironment and microglia reactivity in a human glioblastoma model

doi: 10.1186/s13046-016-0326-y

Figure Lengend Snippet: In vivo effects of peptide R treatment of U87MG orthotopic mouse model. a Tumor volume measures obtained by MRI analyses performed on mice at day 10, 15 and 23 after U87MG cells implantation and drug administration. Curves represent mean value of tumor volumes measures of three independent experiments obtained from mice treated with vehicle (PBS) ● CTRL, ■ Plerixafor and ▲ peptide R ( n = 10 animals per group, error bars ± SD). b Representative brain sections of vehicle-treated (CTRL) or peptide R- or Plerixafor-treated mice stained by immunohistochemistry with the anti-vimentin antibody. Scale bars, 75 μM. c Representative CLSM images of Vimentin expression ( green ) of tumor-free contralateral hemispheres of vehicle-treated mice (CTRL), peptide R- and Plerixafor-treated mice. Arrows represent Vimentin + cells. Nuclei were stained with DAPI ( blue ). Scale bars 75 μM

Article Snippet: The following primary antibodies were used in overnight incubations: rat anti-mouse CD11b (1:100, Serotec), rabbit anti-human CD68 (1:200, able to detect mouse, rat and human CD68, Santa Cruz), mouse anti-mouse Arg-1 (1:200, BD Biosciences), rabbit anti-mouse anti-iNOS (1:2000, Millipore), goat anti-human vimentin (1:40, R&D Systems), rabbit anti-mouse/human glial fibrillary acidic protein, GFAP (1:200, Dako), rat anti-mouse CD31 (1:200, Serotec), mouse anti-human/mouse vascular endothelial growth factor, VEGF (1:50, R&D Systems).

Techniques: In Vivo, Staining, Immunohistochemistry, Expressing

Journal: Clinical and Experimental Immunology

Article Title: Anti‐vimentin/cardiolipin IgA in the anti‐phospholipid syndrome: A new tool for ‘seronegative’ diagnosis

doi: 10.1111/cei.13633

Figure Lengend Snippet: Prevalence of antibodies specific for vimentin/cardiolipin complex.

Article Snippet: Briefly, a 96‐well polystyrene plate (Thermo Fisher Scientific, Waltham, Massachusetts, USA) was coated with 100 μl/well of cardiolipin (50 μg/ml in methanol) (from bovine heart; Sigma‐Aldrich, St Louis, Missouri, USA) and human recombinant vimentin (5 μg/ml in 0.05 mM NaHCO 3 buffer, pH 9.5) (R&D Systems, Minneapolis, Minnesota, USA).

Techniques:

Journal: Clinical and Experimental Immunology

Article Title: Anti‐vimentin/cardiolipin IgA in the anti‐phospholipid syndrome: A new tool for ‘seronegative’ diagnosis

doi: 10.1111/cei.13633

Figure Lengend Snippet: Levels of anti‐vimentin/cardiolipin (aVim/CL) immunoglobulin (Ig)A in patients [anti‐phospholipid syndrome (APS), seronegative (SN)‐APS] and in healthy controls (HC). For detection of aVim/CL IgA all the sera were analyzed by enzyme‐linked immunosorbent assay (ELISA). The cut‐off level has been calculated as the 99th percentile of 40 HC sera

Article Snippet: Briefly, a 96‐well polystyrene plate (Thermo Fisher Scientific, Waltham, Massachusetts, USA) was coated with 100 μl/well of cardiolipin (50 μg/ml in methanol) (from bovine heart; Sigma‐Aldrich, St Louis, Missouri, USA) and human recombinant vimentin (5 μg/ml in 0.05 mM NaHCO 3 buffer, pH 9.5) (R&D Systems, Minneapolis, Minnesota, USA).

Techniques: Enzyme-linked Immunosorbent Assay

Journal: Clinical and Experimental Immunology

Article Title: Anti‐vimentin/cardiolipin IgA in the anti‐phospholipid syndrome: A new tool for ‘seronegative’ diagnosis

doi: 10.1111/cei.13633

Figure Lengend Snippet: Distribution of positive seronegative‐anti‐phospholipid syndrome (SN‐APS) patients among those tested positive for at least one immunoglobulin (Ig)A assay: anti‐cardiolipin (aCL), anti‐β2‐glycoprotein I (aβ2‐GPI); anti‐vimentin/cardiolipin (aVim/CL)

Article Snippet: Briefly, a 96‐well polystyrene plate (Thermo Fisher Scientific, Waltham, Massachusetts, USA) was coated with 100 μl/well of cardiolipin (50 μg/ml in methanol) (from bovine heart; Sigma‐Aldrich, St Louis, Missouri, USA) and human recombinant vimentin (5 μg/ml in 0.05 mM NaHCO 3 buffer, pH 9.5) (R&D Systems, Minneapolis, Minnesota, USA).

Techniques:

Journal: Clinical and Experimental Immunology

Article Title: Anti‐vimentin/cardiolipin IgA in the anti‐phospholipid syndrome: A new tool for ‘seronegative’ diagnosis

doi: 10.1111/cei.13633

Figure Lengend Snippet: Receiver operating characteristic (ROC) analysis of seronegative‐anti‐phospholipid syndrome (SN‐APS). A Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI‐2K) variation presented an area under the curve (AUC) of 0.697 [95% confidence interval (CI) = 0.628–0.766, p < 0.0005]. The variation in anti‐vimentin/cardiolipin (aVim/CL) immunoglobulin (Ig)A levels presented an area under the curve (AUC) of 0.75 (95% CI = 0.645–0.856, p < 0.0001, Youden’s J = 0.213) for the development of thrombotic or pregnancy events, as indicated in the APS classification criteria

Article Snippet: Briefly, a 96‐well polystyrene plate (Thermo Fisher Scientific, Waltham, Massachusetts, USA) was coated with 100 μl/well of cardiolipin (50 μg/ml in methanol) (from bovine heart; Sigma‐Aldrich, St Louis, Missouri, USA) and human recombinant vimentin (5 μg/ml in 0.05 mM NaHCO 3 buffer, pH 9.5) (R&D Systems, Minneapolis, Minnesota, USA).

Techniques: Activity Assay

Journal: Scientific Reports

Article Title: LBPs NPs suppress breast cancer progression by inhibiting YAP1 expression to induce ferroptosis and alter energy metabolism

doi: 10.1038/s41598-025-34454-w

Figure Lengend Snippet: LBPs abrogate YAP1 -overexpression-induced augmentation of mitochondrial function and upregulation of related factor expression in human mammary epithelial cells. ( A , B ) MMP changes were assessed with the JC-1 fluorescent probe in MCF 10A cells following LBPs treatment or transfection with the YAP1 -overexpression plasmid. Data are presented as the mean ± SD ( n = 3), *** P < 0.001. Scale bar, 50 μm. ( C , D ) Representative fluorescence images illustrating ATP probe expression after transfection of pCMV-Mito-AT1.03 into MCF 10A cells that had been subjected to LBPs treatment or transfected with the YAP1 -overexpression plasmid. Data are presented as the mean ± SD ( n = 3), *** P < 0.001. Scale bar, 50 μm. ( E , F ) RT-qPCR analysis of the relative mRNA expression of YAP1 and TAZ in MCF 10A cells following LBPs treatment or transfection with the YAP1 -overexpression plasmid. Data are presented as the mean ± SD ( n = 3), *** P < 0.001. ( G ) Western blot analysis of YAP1 , TAZ , MMP2 , MMP9 , Vimentin protein expression in MCF 10A cells following LBPs treatment or transfection with the YAP1 -overexpression plasmid. ( H – L ) The gray blots were analyzed with ImageJ software ( n = 3). *** P < 0.001.

Article Snippet: After that, the membranes were incubated with primary antibodies: MMP2 (1:1000; Cat No. 10373-2-AP; Proteintech, Wuhan, China), MMP9 (1:1000; AF5228; Affinity, Liyang, China), Vimentin (1:2000; bs-8533R; Bioss, Beijing, China), TAZ (1:1000; bs-12367R; Bioss, Beijing, China), YAP1 (1:1000; bs-3605R; Bioss, Beijing, China), p-YAP1(1:1000; AF3328; Affinity, Liyang, China), ACSL4 (1:1000; DF12141, Affinity, Liyang, China), GPX4 (1:1000; Cat No. 67763-1-Ig; Proteintech, Wuhan, China), β-actin (1:10000; Cat No.20536-1-AP; Proteintech, Wuhan, China).

Techniques: Over Expression, Expressing, Transfection, Plasmid Preparation, Fluorescence, Quantitative RT-PCR, Western Blot, Software